Vision Retirement’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vision Retirement’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$331	–	626
2026 Q1	$331	Buy	+1	New	+$340	﹤0.01%	630

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vision Retirement's ALNY Position: Q2 2026 in Review

Vision Retirement sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1 share — an estimated $331 sold.

Vision Retirement first reported a position in ALNY in Q1 2026 and held it in 1 quarter. The position peaked at $331 in Q1 2026. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Vision Retirement reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Vision Retirement sold 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $331.
Vision Retirement first reported a position in Alnylam Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Vision Retirement's Alnylam Pharmaceuticals position peaked at $331 in Q1 2026.
733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vision Retirement's 13F filing for Q2 2026, filed 21 Jul 2026.